Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

521.88 +40.40 (+8.39%)
Streaming Delayed Price Updated: 11:29 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q3, starting with United... 
Via StockStory
Topics Artificial Intelligence
News headline image
$100 Million Exit: Why One Fund Walked Away From a Chinese E-Commerce Stock Up 24% ↗
Vipshop Holdings is a major Chinese e-commerce retailer specializing in branded discount sales for value-focused consumers. 
Via The Motley Fool
Topics Economy
News headline image
This Bank Stock Just Saw a $24 Million Fund Sale, but Here's Why It's Still a Top Holding ↗
Popular, Inc. offers retail and commercial banking services across Puerto Rico, the U.S., and the British Virgin Islands. 
Via The Motley Fool
Topics Credit Cards ETFs
News headline image
Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at therapeutics stocks, starting with United... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Market-Beating Stocks to Target This Week
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
Topics Credit Cards Supply Chain
News headline image
Investment Advisor Doubles Down on Insurance Stock, According to Recent SEC Filing ↗
This specialty insurer delivers tailored property and casualty coverage for commercial and individual clients across diverse sectors. 
Via The Motley Fool
Topics Bonds Regulatory Compliance
News headline image
Nepsis Bets on CAVA's Future Growth Plan With $2.9 Million Purchase ↗
This fast-casual chain pairs Mediterranean dining with grocery retail, leveraging a vertically integrated, multi-channel strategy. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
2 Cash-Heavy Stocks to Target This Week and 1 We Question
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
News headline image
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Biogen (NASDAQ:BIIB) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Why a $27 Million Buy Signals New Confidence in Weatherford Stock ↗
One global services provider just landed a long list of new contracts — and a major fund has quietly built a sizable stake. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy? ↗
One major fund is betting that Signet’s margin rebound is just getting started. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock ↗
One value-focused hedge fund just doubled down on one of North America’s biggest coal exporters — here’s what that could mean for the stock’s next chapter. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? ↗
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Value Investing Case Study ↗
United Therapeutics (UTHR) presents a compelling value investment case with strong profitability, a debt-free balance sheet, and a valuation discounted relative to its biotech sector peers. 
Via Chartmill
News headline image
United Therapeutics Corp (NASDAQ:UTHR): A Caviar Cruise Quality Investment ↗
United Therapeutics (UTHR) excels as a Caviar Cruise quality stock with strong growth, high profitability, a debt-free balance sheet, and exceptional returns on capital. 
Via Chartmill
News headline image
2 Mooning Stocks on Our Buy List and 1 That Underwhelm
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Here's How Much $100 Invested In United Therapeutics 15 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
United Therapeutics Corp (NASDAQ:UTHR) Presents a Compelling Value Investment Case ↗
United Therapeutics (UTHR) offers strong value with a low P/E ratio, zero debt, and high profitability. This biotech stock presents a compelling opportunity for value investors. 
Via Chartmill
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
United Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 44.4%, reaching $448.91 per share. This performance may have investors wondering how to... 
Via StockStory
News headline image
Is United Therapeutics Corp Gaining or Losing Market Support? ↗
 
Via Benzinga
News headline image
P/E Ratio Insights for United Therapeutics ↗
 
Via Benzinga
News headline image
My Top Vanguard Index ETF Pick for 2026 ↗
This ETF has underperformed the S&P 500 lately, but I think that will change. 
Via The Motley Fool
Topics ETFs Economy Stocks
News headline image
The 5 Most Interesting Analyst Questions From United Therapeutics’s Q3 Earnings Call
United Therapeutics delivered a quarter that was well received by the market despite missing revenue expectations, as operational progress and clinical milestones took center stage. Management credited... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
If You Invested $100 In United Therapeutics Stock 5 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
United Therapeutics Corporation to Present at Upcoming Investor Conferences
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
From United Therapeutics Corporation
Via Business Wire
News headline image
2 Safe-and-Steady Stocks with Impressive Fundamentals and 1 We Avoid
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.